Detalhe da pesquisa
1.
Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
Mod Pathol
; 37(3): 100420, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185249
2.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357801
3.
Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
Mod Pathol
; 36(3): 100030, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788094
4.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Br J Cancer
; 126(6): 889-898, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963703
5.
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
Cancer
; 125(24): 4380-4387, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31469421
6.
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Acta Oncol
; 58(11): 1634-1639, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31347936
7.
ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma.
Lancet Oncol
; 23(4): 445-446, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358447
8.
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice.
Oncologist
; 27(8): 610-614, 2022 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708504
9.
Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.
Annu Rev Pathol
; 19: 11-42, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37722697
10.
Safety and efficacy of percutaneous cryoablation for primary and metastatic pleural based tumors.
Eur J Radiol
; 175: 111465, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621339
11.
Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features.
Clin Cancer Res
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630790
12.
Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation.
Radiother Oncol
; 190: 109983, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37926331
13.
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.
Radiother Oncol
; 191: 110057, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104783
14.
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.
JAMA Netw Open
; 6(1): e2249591, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602799
15.
Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting.
Cancer Cytopathol
; 131(8): 495-506, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127928
16.
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
J Clin Oncol
; 41(21): 3700-3711, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270692
17.
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
JAMA Netw Open
; 6(3): e232526, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36897589
18.
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma.
JTO Clin Res Rep
; 4(1): 100440, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36590015
19.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Cancer Discov
; 13(11): 2412-2431, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552839
20.
Molecular Characterization of Peritoneal Mesotheliomas.
J Thorac Oncol
; 17(3): 455-460, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648949